Sub menu

 

 

CIPLA APREMILAST (Cipla Australia Pty Ltd)

Product name
CIPLA APREMILAST
Sponsor
Cipla Australia Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
164 (255 working days)
Active ingredients
apremilast
Registration type
New generic medicine
Indication

Cipla Apremilast is indicated for:

  • The treatment of signs and symptoms of active psoriatic arthritis in adult patients
  • The treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy
  • The treatment of adult patients with oral ulcers associated with Behçet’s Disease who are candidates for systemic therapy